Literature DB >> 16452196

An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis.

Kazuyuki Matsushita1, Takeshi Tomonaga, Hideaki Shimada, Ayumi Shioya, Morihiro Higashi, Hisahiro Matsubara, Kenichi Harigaya, Fumio Nomura, Daniel Libutti, David Levens, Takenori Ochiai.   

Abstract

Elevated expression of c-myc has been detected in a broad range of human cancers, indicating a key role for this oncogene in tumor development. Recently, an interaction between FUSE-binding protein-interacting repressor (FIR) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and might be important for suppressing tumor formation. In this study, we showed that enforced expression of FIR induced apoptosis. Deletion of the NH(2)-terminal repression domain of FIR rescued the cells from apoptosis as did coexpression of c-Myc with FIR; thus, repression of Myc mediates FIR-driven apoptosis. Surprisingly, a splicing variant of FIR unable to repress c-myc or to drive apoptosis was frequently discovered in human primary colorectal cancers but not in the adjacent normal tissues. Coexpression of this splicing variant with repressor-competent FIR, either in HeLa cells or in the colon cancer cell line SW480, not only abrogated c-Myc suppression but also inhibited apoptosis. These results strongly suggest the expression of this splicing variant promotes tumor development by disabling FIR repression and sustaining high levels of c-Myc and opposing apoptosis in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452196     DOI: 10.1158/0008-5472.CAN-04-4459

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  The implications of alternative splicing in the ENCODE protein complement.

Authors:  Michael L Tress; Pier Luigi Martelli; Adam Frankish; Gabrielle A Reeves; Jan Jaap Wesselink; Corin Yeats; Páll Isólfur Olason; Mario Albrecht; Hedi Hegyi; Alejandro Giorgetti; Domenico Raimondo; Julien Lagarde; Roman A Laskowski; Gonzalo López; Michael I Sadowski; James D Watson; Piero Fariselli; Ivan Rossi; Alinda Nagy; Wang Kai; Zenia Størling; Massimiliano Orsini; Yassen Assenov; Hagen Blankenburg; Carola Huthmacher; Fidel Ramírez; Andreas Schlicker; France Denoeud; Phil Jones; Samuel Kerrien; Sandra Orchard; Stylianos E Antonarakis; Alexandre Reymond; Ewan Birney; Søren Brunak; Rita Casadio; Roderic Guigo; Jennifer Harrow; Henning Hermjakob; David T Jones; Thomas Lengauer; Christine A Orengo; László Patthy; Janet M Thornton; Anna Tramontano; Alfonso Valencia
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

2.  Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.

Authors:  Kazuyuki Matsushita; Hideaki Shimada; Yasuji Ueda; Makoto Inoue; Mamoru Hasegawa; Takeshi Tomonaga; Hisahiro Matsubara; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 4.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

5.  Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer.

Authors:  N Tanaka; K Araki; D Mizokami; Y Miyagawa; T Yamashita; M Tomifuji; Y Ueda; M Inoue; K Matsushita; F Nomura; H Shimada; A Shiotani
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

6.  Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models.

Authors:  Jue Er Amanda Lee; Naomi C Mitchell; Olga Zaytseva; Arjun Chahal; Peter Mendis; Amandine Cartier-Michaud; Linda M Parsons; Gretchen Poortinga; David L Levens; Ross D Hannan; Leonie M Quinn
Journal:  Nat Commun       Date:  2015-06-15       Impact factor: 14.919

7.  The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy.

Authors:  Ya-Mei Zhang; Han-Bo Yang; Jing-Li Shi; He Chen; Xiao-Ming Shu; Xin Lu; Guo-Chun Wang; Qing-Lin Peng
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

8.  PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.

Authors:  David F Fiorentino; Matthew Presby; Alan N Baer; Michelle Petri; Kerri E Rieger; Mark Soloski; Antony Rosen; Andrew L Mammen; Lisa Christopher-Stine; Livia Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2015-08-07       Impact factor: 19.103

9.  Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.

Authors:  Kazuyuki Matsushita; Mai Tamura; Nobuko Tanaka; Takeshi Tomonaga; Hisahiro Matsubara; Hideaki Shimada; David Levens; Liusheng He; Juhong Liu; Minoru Yoshida; Fumio Nomura
Journal:  Mol Cancer Res       Date:  2013-04-17       Impact factor: 5.852

10.  Molecular basis of FIR-mediated c-myc transcriptional control.

Authors:  Cyprian D Cukier; David Hollingworth; Stephen R Martin; Geoff Kelly; Irene Díaz-Moreno; Andres Ramos
Journal:  Nat Struct Mol Biol       Date:  2010-08-15       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.